Pub. Date : 1997 May
PMID : 9186825
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). | Ribavirin | interferon alpha 1 | Homo sapiens |
2 | The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). | Ribavirin | interferon alpha 1 | Homo sapiens |
3 | The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). | Ribavirin | interferon alpha 1 | Homo sapiens |
4 | The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). | Ribavirin | interferon alpha 1 | Homo sapiens |
5 | The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. | Ribavirin | interferon alpha 1 | Homo sapiens |
6 | The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. | Ribavirin | interferon alpha 1 | Homo sapiens |
7 | The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. | Ribavirin | interferon alpha 1 | Homo sapiens |